SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is the main focus, especially mature frontline melanoma results for lifileucel plus pembrolizumab and early sarcoma findings. Traders highlight durable melanoma responses as supportive of expansion into earlier treatment, while others caution that the cohorts are small and the sarcoma response rate eased as the sample grew.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A Nasdaq-futures rebound around the 1987 Black Monday anniversary is dominating discussion after a steep tech-led selloff, with big-tech earnings ahead. Traders are split on whether the bounce is a durable recovery or a short-covering rally that could fade, while AI-stock weakness and broader market risks remain concerns.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A broad selloff in AI neocloud stocks, driven by worries about debt, financing costs, and whether rapid data-center spending can earn adequate returns, has weighed on Nebius alongside peers. Traders are divided: bears see further valuation pressure, while bulls argue Nebius is better positioned than more leveraged rivals and view the drop as an overdone sector-wide move.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after last weeks tech-led selloff has shifted the conversation to whether the bounce will hold, amid fears tied to the Black Monday anniversary. Bulls call it a relief rally or short squeeze and dismiss crash worries, while skeptics warn the move may fade; upcoming megacap earnings add to market focus.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Lingering concerns over weak guidance, slowing ad-spend growth, and competition in digital advertising are weighing on Trade Desk shares. Traders remain divided between expecting further declines until growth and execution improve and viewing the selloff and high short interest as a potential setup for a rebound.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention amid a sharp, extended semiconductor selloff, with traders questioning whether heavy AI infrastructure spending can deliver sufficient returns and citing inflation, rates, and competitive pressures as additional headwinds. The community is split between expecting an oversold bounce and warning that the pullback could deepen into a broader correction.

Direxion Shares ETF Trust - Direxion Daily MU Bull 2X ETF

Direxion Daily MU Bull 2X Shares

MUU is drawing attention after a sharp selloff alongside Micron and other memory stocks, with traders debating whether the drop is a dip-buying opportunity or a sign of further downside. Some attribute the weakness to South Korean market moves and concerns around AI and memory demand, while others point to the funds leverage as amplifying its volatility.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

The discussion centers on shifting leadership between the Magnificent Seven and semiconductors/AI infrastructure, with traders debating whether MAGS can resume leading after a pullback. Some see renewed mega-cap strength and breakout potential, while others point to recent weakness and worry that money is rotating elsewhere.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This HC Wainwright & Co. Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Wall Street analysts began coverage on top names, including a bullish rating on Radiopharm Theranostics. See more analyst ratings.read more...

Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference

Radiopharm Theranostics (NASDAQ:RADX) outlined progress across its radiopharmaceutical pipeline and highlighted near-term clinical catalysts during a presentation at the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference.

Chief Executive Officer Riccardo Canevari described the compa...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Decrease in Short Interest

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totaling...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Sees Significant Growth in Short Interest

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 31st, there was...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four analysts that are presently covering...

Radiopharm Theranostics Signs Supply Deal With Siemens Healthineers For RAD101

(RTTNews) - Radiopharm Theranostics Ltd. (RADX) said Tuesday it has signed a supply agreement with Siemens Healthineers for RAD101, a novel imaging small molecule targeting fatty acid synthase (FASN) to diagnose suspected recurrent brain metastases from solid tumors...

Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study

Radiopharm Theranostics (NASDAQ:RADX) executives and clinical investigators highlighted new interim findings from the company's ongoing Phase IIb study of RAD101, a PET imaging tracer intended to...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Average Rating of "Buy" by Brokerages

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have been given an average recommendation of "Buy" by the five analysts that are covering the firm...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Short Interest Update

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there...

Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of "Buy" by Brokerages

Shares of Radiopharm Theranostics Limited - Sponsored ADR (NASDAQ:RADX - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are currently covering the stock...

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$1.03
Prev Close	$1.08
Open	$1.02
Dividend Yield	0.00%
50-Day Moving Average	$1.91
Beta	0.00
Avg. Volume	51,480.66
PE Ratio	-0.32

52-Week High	$16.25
52-Week Low	$0.9001
Market Capitalization	$16.17M
EPS (Annual)	-$3.65
Price to Book	0.71
Revenue Per Employee	$133,970.29

Feed

News

Sentiment

Fundamentals

Info

RADX Fundamentals